WEBULL
WebtradeDownload

Why 10x Genomics (TXG) Is Up 21.7% After Raising 2026 Outlook Despite Q2 Revenue Drop

Simply Wall St · 1d ago
  • In August 2026, 10x Genomics, Inc. reported that second-quarter revenue fell to US$151.04 million from US$172.91 million a year earlier, moving from net income of US$34.54 million to a net loss of US$17.93 million, but simultaneously raised its full-year 2026 revenue guidance to US$610 million–US$630 million from US$600 million–US$625 million.
  • This combination of weaker recent results and a slightly higher full-year outlook highlights a tension between current operating pressure and management’s confidence in the business pipeline.
  • We’ll now examine how raising full-year revenue guidance, despite softer recent results, could influence 10x Genomics’ broader investment narrative.

Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

10x Genomics Investment Narrative Recap

To own 10x Genomics, you need to believe its single cell and spatial tools can become essential infrastructure for precision medicine, despite current losses and funding headwinds. The latest quarter’s weaker revenue and swing to a net loss underline short term pressure, but the small guidance raise suggests management still sees demand holding up. For now, the most important near term catalyst remains execution on new product ramps, while persistent operating losses stay the biggest risk.

The most relevant recent announcement here is the August 2026 guidance revision, lifting full year revenue expectations to US$610 million to US$630 million. That move, coming alongside softer first half results, tightens the focus on whether collaborations and platform launches like Atera and Xenium can translate into steadier consumables demand. How quickly these newer offerings gain traction will matter for validating the improved outlook and easing concerns around profitability and research funding exposure.

But against this, investors should also be aware of the risk that rising competition and weaker instrument demand could still...

Read the full narrative on 10x Genomics (it's free!)

10x Genomics' narrative projects $754.6 million revenue and $120.2 million earnings by 2029. This requires 5.7% yearly revenue growth and a $142.9 million earnings increase from -$22.7 million today.

Uncover how 10x Genomics' forecasts yield a $41.54 fair value, a 28% downside to its current price.

Exploring Other Perspectives

TXG 1-Year Stock Price Chart
TXG 1-Year Stock Price Chart

Some of the most optimistic analysts were assuming revenue could reach about US$828 million by 2029 with a sharp margin improvement, so compared with the current guidance tweak and concerns about competition and softer instrument sales, you can see how far apart views can be and why this latest report might eventually shift those expectations.

Explore 4 other fair value estimates on 10x Genomics - why the stock might be worth less than half the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Looking For Alternative Opportunities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.